Alphanate

"The U.S. Food and Drug Administration today expanded the approved use of Xgeva (denosumab) to treat adults and some adolescents with giant cell tumor of the bone (GCTB), a rare and usually non-cancerous tumor.

SIDE EFFECTS

Occasionally, mild reactions occur following the administration of Antihemophilic
Factor (Human)13, such as allergic reactions, chills, nausea, or
stinging at the infusion site. If a reaction is experienced, and the patient
requires additional Antihemophilic Factor (Human), product from a different
lot should be administered.

Massive doses of Antihemophilic Factor (Human) have rarely resulted in acutehemolytic anemia, increased bleeding tendency or hyperfibrinogenemia.14
Alphanate (antihemophilic factor) ® contains blood group specific isoagglutinins and, when
large and/or frequent doses are required in patients of blood groups A, B, or
AB, the patient should be monitored for signs of intravascular hemolysis and
falling hematocrit. Should this condition occur, thus leading to progressive emolytic anemia, the administration of serologically compatible type O red
blood cells should be considered or the administration of Antihemophilic Factor
(Human) produced from group-specific plasma should be considered.